NO312807B1 - Blanding for et skum og skum, spesielt for rektal anvendelse, samt fremgangsmåte for fremstilling derav - Google Patents
Blanding for et skum og skum, spesielt for rektal anvendelse, samt fremgangsmåte for fremstilling derav Download PDFInfo
- Publication number
- NO312807B1 NO312807B1 NO19962512A NO962512A NO312807B1 NO 312807 B1 NO312807 B1 NO 312807B1 NO 19962512 A NO19962512 A NO 19962512A NO 962512 A NO962512 A NO 962512A NO 312807 B1 NO312807 B1 NO 312807B1
- Authority
- NO
- Norway
- Prior art keywords
- foam
- surfactant
- mixture
- mixture according
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 239000006260 foam Substances 0.000 title claims abstract description 93
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002245 particle Substances 0.000 claims abstract description 16
- 239000003380 propellant Substances 0.000 claims abstract description 16
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical group NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 19
- 229960004963 mesalazine Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920001983 poloxamer Polymers 0.000 claims description 7
- 238000010348 incorporation Methods 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 230000003232 mucoadhesive effect Effects 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 description 19
- 238000009472 formulation Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000007789 gas Substances 0.000 description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 9
- 238000011049 filling Methods 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000000664 rectum Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 239000006265 aqueous foam Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008387 emulsifying waxe Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000001282 iso-butane Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 101100506034 Fibrobacter succinogenes (strain ATCC 19169 / S85) cel-3 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKMOQBVBEGCJGW-LLIZZRELSA-L OC1=CC=C(C=C1C(=O)O[Na])\N=N\C1=CC=C(C=C1)C(=O)NCCC(=O)O[Na] Chemical compound OC1=CC=C(C=C1C(=O)O[Na])\N=N\C1=CC=C(C=C1)C(=O)NCCC(=O)O[Na] CKMOQBVBEGCJGW-LLIZZRELSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008258 liquid foam Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyurethanes Or Polyureas (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9314973A FR2713486B1 (fr) | 1993-12-14 | 1993-12-14 | Nouvelles compositions pour mousses, notamment mousses rectales, et mousses ainsi obtenues. |
PCT/FR1994/001463 WO1995016433A1 (fr) | 1993-12-14 | 1994-12-14 | Nouvelles compositions pour mousses, notamment mousses rectales, et mousses ainsi obtenues |
Publications (3)
Publication Number | Publication Date |
---|---|
NO962512D0 NO962512D0 (no) | 1996-06-13 |
NO962512L NO962512L (no) | 1996-08-08 |
NO312807B1 true NO312807B1 (no) | 2002-07-08 |
Family
ID=9453888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19962512A NO312807B1 (no) | 1993-12-14 | 1996-06-13 | Blanding for et skum og skum, spesielt for rektal anvendelse, samt fremgangsmåte for fremstilling derav |
Country Status (19)
Country | Link |
---|---|
US (1) | US5725872A (de) |
EP (1) | EP0735860B1 (de) |
JP (1) | JP2886688B2 (de) |
KR (1) | KR100231767B1 (de) |
AT (1) | ATE179596T1 (de) |
AU (1) | AU692815B2 (de) |
CA (1) | CA2179019C (de) |
CZ (1) | CZ291272B6 (de) |
DE (2) | DE69418342T2 (de) |
DK (1) | DK0735860T3 (de) |
ES (1) | ES2093587T3 (de) |
FI (1) | FI114139B (de) |
FR (1) | FR2713486B1 (de) |
GR (1) | GR3030348T3 (de) |
HU (1) | HUT74515A (de) |
NO (1) | NO312807B1 (de) |
NZ (1) | NZ277507A (de) |
PL (1) | PL178490B1 (de) |
WO (1) | WO1995016433A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
IL132522A0 (en) | 1997-04-22 | 2001-03-19 | Cocensys Inc | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and pharmaceutical compositions containing the same |
GB2335596A (en) | 1998-03-24 | 1999-09-29 | Procter & Gamble | Polyalkyleneglycol Copolymers as Lipase Inhibitors |
DE19849737A1 (de) * | 1998-10-28 | 2000-05-04 | Falk Pharma Gmbh | Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
TWI249519B (en) | 2000-08-29 | 2006-02-21 | Nobex Corp | Immunoregulatory compounds and derivatives and methods of treating diseases therewith |
US8048924B2 (en) * | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
ES2532906T5 (es) | 2002-10-25 | 2022-03-23 | Foamix Pharmaceuticals Ltd | Espuma cosmética y farmacéutica |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7575739B2 (en) * | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
JP2007503428A (ja) * | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー. | 浸透性医薬発泡剤 |
US7932366B2 (en) | 2004-07-07 | 2011-04-26 | Biocon Limited | Synthesis of azo bonded immunoregulatory compounds |
DE202005011885U1 (de) * | 2005-07-28 | 2006-08-31 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Geschäumte Zubereitung |
EP1810666A1 (de) | 2006-01-19 | 2007-07-25 | Ferring International Center S.A. | Schaumbildende Präparate |
JP5184373B2 (ja) * | 2006-01-19 | 2013-04-17 | ディスファー・インターナショナル・ベー・フェー | 発泡組成物 |
US20080206155A1 (en) * | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080292560A1 (en) * | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
US7645801B2 (en) * | 2007-01-29 | 2010-01-12 | Alaven Pharmaceutical Llc | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
JP2010526945A (ja) * | 2007-05-09 | 2010-08-05 | バックマン・ラボラトリーズ・インターナショナル・インコーポレーテッド | 紙及び板紙用のasaサイジングエマルジョン |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
WO2009150530A2 (en) * | 2008-06-11 | 2009-12-17 | Ferring International Center Sa | Novel foam composition |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
MX359879B (es) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Composiciones tópicas de tetraciclina. |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
MX2017011630A (es) | 2016-09-08 | 2018-09-25 | Foamix Pharmaceuticals Ltd | Composiciones y metodos para tratar rosacea y acne. |
AU2017377017A1 (en) * | 2016-12-16 | 2019-07-04 | Ferring B.V. | Rectal foam formulations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8909559D0 (en) * | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
FR2647344B1 (fr) * | 1989-05-25 | 1995-06-02 | Physiopharm Sarl | Mousse aerosol a usage rectal |
EP0533938A4 (en) * | 1991-02-19 | 1993-06-16 | Tsumura & Co. | Composition for rectal administration of difficultly absorbable peptide |
-
1993
- 1993-12-14 FR FR9314973A patent/FR2713486B1/fr not_active Expired - Fee Related
-
1994
- 1994-12-14 DE DE69418342T patent/DE69418342T2/de not_active Expired - Fee Related
- 1994-12-14 JP JP7516569A patent/JP2886688B2/ja not_active Expired - Lifetime
- 1994-12-14 AT AT95903833T patent/ATE179596T1/de not_active IP Right Cessation
- 1994-12-14 ES ES95903833T patent/ES2093587T3/es not_active Expired - Lifetime
- 1994-12-14 WO PCT/FR1994/001463 patent/WO1995016433A1/fr active IP Right Grant
- 1994-12-14 CZ CZ19961756A patent/CZ291272B6/cs not_active IP Right Cessation
- 1994-12-14 KR KR1019960703224A patent/KR100231767B1/ko not_active IP Right Cessation
- 1994-12-14 DK DK95903833T patent/DK0735860T3/da active
- 1994-12-14 NZ NZ277507A patent/NZ277507A/en not_active IP Right Cessation
- 1994-12-14 AU AU12753/95A patent/AU692815B2/en not_active Ceased
- 1994-12-14 CA CA002179019A patent/CA2179019C/fr not_active Expired - Fee Related
- 1994-12-14 EP EP95903833A patent/EP0735860B1/de not_active Expired - Lifetime
- 1994-12-14 DE DE0735860T patent/DE735860T1/de active Pending
- 1994-12-14 PL PL94315032A patent/PL178490B1/pl not_active IP Right Cessation
- 1994-12-14 HU HU9601628A patent/HUT74515A/hu not_active IP Right Cessation
-
1996
- 1996-06-13 NO NO19962512A patent/NO312807B1/no unknown
- 1996-06-14 FI FI962478A patent/FI114139B/fi active
- 1996-09-17 US US08/663,049 patent/US5725872A/en not_active Expired - Fee Related
-
1999
- 1999-05-27 GR GR990401437T patent/GR3030348T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
US5725872A (en) | 1998-03-10 |
FI962478A (fi) | 1996-06-14 |
GR3030348T3 (en) | 1999-09-30 |
DE735860T1 (de) | 1997-06-26 |
DE69418342T2 (de) | 1999-11-04 |
FI962478A0 (fi) | 1996-06-14 |
NZ277507A (en) | 1997-09-22 |
HUT74515A (en) | 1997-01-28 |
HU9601628D0 (en) | 1996-08-28 |
ES2093587T1 (es) | 1997-01-01 |
JP2886688B2 (ja) | 1999-04-26 |
NO962512D0 (no) | 1996-06-13 |
CA2179019A1 (fr) | 1995-06-22 |
CZ175696A3 (en) | 1997-04-16 |
FR2713486B1 (fr) | 1996-02-09 |
CZ291272B6 (cs) | 2003-01-15 |
FI114139B (fi) | 2004-08-31 |
FR2713486A1 (fr) | 1995-06-16 |
WO1995016433A1 (fr) | 1995-06-22 |
JPH09506605A (ja) | 1997-06-30 |
ES2093587T3 (es) | 1999-07-16 |
AU1275395A (en) | 1995-07-03 |
CA2179019C (fr) | 2002-03-19 |
PL315032A1 (en) | 1996-09-30 |
DE69418342D1 (de) | 1999-06-10 |
AU692815B2 (en) | 1998-06-18 |
KR100231767B1 (ko) | 1999-11-15 |
EP0735860A1 (de) | 1996-10-09 |
NO962512L (no) | 1996-08-08 |
ATE179596T1 (de) | 1999-05-15 |
DK0735860T3 (da) | 1999-11-01 |
EP0735860B1 (de) | 1999-05-06 |
PL178490B1 (pl) | 2000-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO312807B1 (no) | Blanding for et skum og skum, spesielt for rektal anvendelse, samt fremgangsmåte for fremstilling derav | |
AU726382B2 (en) | Medicinal aerosol formulations of formoterol | |
JP3142136B2 (ja) | 加圧エアロゾル組成物 | |
US6054488A (en) | Medicinal aerosol formulations of formoterol | |
JPH05507712A (ja) | 加圧エアロゾル組成物 | |
CZ184694A3 (en) | Pharmaceutical preparation | |
NO332848B1 (no) | Medisinske aerosolformuleringer, trykkgassbeholder omfattende denne, fremgangsmate for fremstilling av formuleringene samt anvendelse av hjelpestoffer i nevnte formuleringer. | |
JP2004502719A (ja) | 極性のフッ素化された分子を含む新規エアゾール製剤 | |
JPH08505845A (ja) | 水性リキッドパウダー | |
US5378470A (en) | Rectally administered pharmaceutical preparation | |
NO163042B (no) | Fremgangsmaate ved fremstilling av stabiliserte pge2- forbindelser. | |
JP2003518036A (ja) | オキシカルバゼピン含有懸濁剤 | |
GB2443161A (en) | Spray foaming dosage form comprising clobetasol propionate | |
Sharwaree et al. | Development of mucoadhesive nasal in-situ gel to sustain the release of amitriptyline hydrochloride | |
AU645366B2 (en) | Aerosol composition and a process preparing same | |
WO2009150530A2 (en) | Novel foam composition | |
WO2023078073A1 (zh) | 一种包含孕激素的新型口服制剂及制备方法和应用 | |
JPH0160451B2 (de) |